prikaz prve stranice dokumenta TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study
  Download
PDF 1.68 MB
Scientific paper - Original scientific paper
TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study
Microorganisms, 11 (2023), 6; 1571. https://doi.org/10.3390/microorganisms11061571
Šušak, Frano; Vrsaljko, Nina; Vince, Adriana; Papić, Neven

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šušak, F., Vrsaljko, N., Vince, A. & Papić, N. (2023). TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study. Microorganisms, 11. (6). doi: 10.3390/microorganisms11061571

Šušak, Frano, et al. "TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study." Microorganisms, vol. 11, no. 6, 2023. https://doi.org/10.3390/microorganisms11061571

Šušak, Frano, Nina Vrsaljko, Adriana Vince and Neven Papić. "TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study." Microorganisms 11, no. 6 (2023). https://doi.org/10.3390/microorganisms11061571

Šušak, F., et al. (2023) 'TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study', Microorganisms, 11(6). doi: 10.3390/microorganisms11061571

Šušak F, Vrsaljko N, Vince A, Papić N. TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study. Microorganisms [Internet]. 2023 June 13 [cited 2024 November 26];11(6). doi: 10.3390/microorganisms11061571

F. Šušak, N. Vrsaljko, A. Vince and N. Papić, "TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study", Microorganisms, vol. 11, no. 6, June 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:219307. [Accessed: 26 November 2024]

Metadata
Title (english)TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD: A Prospective Case – Control Study
AuthorFrano Šušak
AuthorNina Vrsaljko
AuthorAdriana Vince
AuthorNeven Papić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 remain unknown. Transforming growth factor-beta 1 (TGF-β1) has an important immunomodulatory and pro-fibrotic role, which has already been described in NAFLD. However, the role of TGF-β1 in COVID-19 remains unclear, and could also be the pathophysiology link between these two conditions. The aim of this case–control study was to analyze the expression of TGF-β1 in COVID-19 patients depending on the presence of NAFLD and COVID-19 severity. Serum TGF-β1 concentrations were measured in 60 hospitalized COVID-19 patients (30 with NAFLD). NAFLD was associated with higher serum TGF-β1 concentrations that increased with disease severity. Admission TGF-β1 concentrations showed good discriminative accuracy in predicting the development of critical disease and COVID-19 complications (need for advanced respiratory support, ICU admission, time to recovery, development of nosocomial infections and mortality). In conclusion, TGF-β1 could be an efficient biomarker for predicting COVID-19 severity and adverse outcomes in patients with NAFLD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMicroorganisms
Numberingvol. 11, no. 6, 1571
e-ISSN2076-2607
DOIhttps://doi.org/10.3390/microorganisms11061571
URN:NBNurn:nbn:hr:105:219307
Publication2023-06-13
ProjectNumber: UIP-2019-04-7194
Title (croatian): Uloga imunih semaforina u nealkoholnoj masnoj bolesti jetre i sepsi
Title (english): The role of immune semaphorins in NAFLD and sepsis
Acronym: SepsisFAT
Leader: Neven Papić
Jurisdiction: Croatia
Funding stream: UIP
Document URLhttps://www.mdpi.com/2076-2607/11/6/1571
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-09-18 09:29:00